Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan-Jun;16(1):7-14.
doi: 10.4103/ajts.ajts_106_21. Epub 2022 Jul 30.

Plerixafor use in autologous hematopoietic stem cell mobilization: Experience from a single center in Southern India

Soumya Das  1   2 , Smita Kayal  3 , Biswajit Dubashi  3 , Abhishekh Basavarajegowda  1 , Nanda Kishore Pasupala  1   4 , Rajendra Kulkarni  1 , Krishnappa Dhanraju  3   5 , Chinmaya Kumar Pani  3   6
Affiliations

Plerixafor use in autologous hematopoietic stem cell mobilization: Experience from a single center in Southern India

Soumya Das et al. Asian J Transfus Sci. 2022 Jan-Jun.

Abstract

Background: Plerixafor is used for patients at risk of Stem cell mobilization failure based on clinical factors or low peripheral blood CD34 count. It is also added upfront to any mobilization irrespective of risk factor, but the cost-effectiveness of the approach is an issue. Data on plerixafor in different settings of autologous hematopoietic stem cell (HSC) collection from India are scant. We are hereby reporting the experience of failure/success of mobilization rate and few important significant variables (CD34+ dosage, failed collection) between plerixafor and granulocyte colony-stimulating factor alone groups among autologous hematopoietic stem cell transplantation (aHSCT) at our institute.

Methods: This was a record-based single-center study on patients who underwent aHSCT from January 2013 to June 2019 at a tertiary care hospital. Descriptive statistics were used for baseline characteristics, transplant-related factors, and peritransplant outcomes. All statistical analyses were performed at the 5% significance level.

Results: During the study duration, a total of 96 patients had undergone autologous hematopoietic stem cell collection (aHSCC), all by peripheral blood stem cell harvest, requiring 131 apheretic collections. Of the total 131 collections in 96 patients, plerixafor was used in 63 apheresis collections (48% of total pheresis) in 40 patients. Among the 40 patients who were administered plerixafor to augment the collection, 34 patients had upfront use of plerixafor. We did not observe any significant adverse event related to plerixafor use.

Conclusion: A rational utilization of plerixafor can facilitate the process and logistics of aHSCC outcome.

Keywords: Autologous hematopoietic stem cell transplantation; India; plerixafor.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Algorithm to show the study participants and summary
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. To LB, Levesque JP, Herbert KE. How i treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011;118:4530–40. - PubMed
    1. Costa LJ, Nista EJ, Buadi FK, Lacy MQ, Dispenzieri A, Kramer CP, et al. Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: Implications for risk-stratification. Biol Blood Marrow Transplant. 2014;20:222–8. - PubMed
    1. Douglas KW, Gilleece M, Hayden P, Hunter H, Johnson PR, Kallmeyer C, et al. UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy. J Clin Apher. 2018;33:46–59. - PubMed
    1. Koepsell SA, Jacob EK, McKenna DH., Jr . The collection and processing of hematopoietic stem cells. In: Fung MK, Grossman BJ, Hillyer CD, Westhoff CM, editors. Technical Manual. Maryland, United States: AABB; 2014. pp. 713–26.
    1. Lane TA, McMannis JD. Hematopoietic progenitor cells collected by apheresis. In: Fung MK, Grossman BJ, Harris T, Hillyer CD, editors. Technical Manual. Maryland, United States: AABB; 2011. pp. 801–22.